October 28, 2020
Article
A new study demonstrates that vedolizumab is associated with real-world corticosteroid-free response and remission in patients with ulcerative colitis and Crohn’s disease.
Anti-TNFs, vedolizumab, ustekinumab, thiopurines, and 5-ASA were all linked to a lower risk of myocardial infarctions.
A poster presented at ACG provides an updated analysis of clostridium difficile infection in the tofacitinib UC clinical program.
October 27, 2020
Researchers test 3 different doses of mirikizumab in both biologic experienced and naïve Crohn’s disease patients.
Video
Ustekinumab resulted in a reduction of both stool frequency and rectal bleeding for ulcerative colitis patients.
More than half of the patient population achieved a defined response at both day 14 and week 6.
October 26, 2020
A new study presented at ACG shows vedolizumab to be superior to adalimumab in maintaining early disease control in patients with moderate-to-severe ulcerative colitis.
In a poster presented during ACG, investigators show data from a long-term extension of the UNIFI trial.
October 20, 2020
Investigators compared 2 groups, before and after the initiation of a biosimilar program at their hospital.
October 15, 2020
Only 29.5% of sampled CBD users claimed any wellness benefit.
